Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$21.93
+0.3%
$21.07
$17.24
$28.56
$14.05B0.941.25 million shs406,471 shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.87
$70.90
$131.98
$14.05B0.691.55 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$32.46
+1.3%
$27.62
$23.15
$126.42
$12.49B1.848.88 million shs3.52 million shs
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$46.99
$46.71
$28.21
$62.00
$3.54B0.682.63 million shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+3.40%+1.34%-4.33%+9.13%-19.00%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%0.00%+67.84%
Moderna, Inc. stock logo
MRNA
Moderna
+1.52%-2.23%+23.31%+29.72%-74.38%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00%0.00%+0.26%+24.02%+12.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3.9269 of 5 stars
3.35.00.00.02.80.03.1
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.9163 of 5 stars
1.10.00.04.51.31.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.2711 of 5 stars
4.01.00.04.62.02.50.6
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
1.6038 of 5 stars
3.12.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.64
Moderate Buy$37.8071.93% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6143.82% Upside
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
2.13
Hold$52.5711.88% Upside

Current Analyst Ratings Breakdown

Latest SWTX, ITCI, GMAB, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
7/8/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/12/2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$50.00 ➝ $32.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.12B4.53$1.58 per share13.95$8.04 per share2.73
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.87N/AN/A$28.33 per share1.14
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$191.59M18.48N/AN/A$6.47 per share7.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.7612.4912.356.4335.11%18.08%14.52%8/14/2025 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%8/6/2025 (Estimated)

Latest SWTX, ITCI, GMAB, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.39N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.97N/AN/AN/A$116.26 millionN/A
8/6/2025Q2 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81N/AN/AN/A$73.39 millionN/A
5/9/2025Q1 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million
5/8/2025Q1 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
5.34
5.32
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
4.33
4.18

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
7.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.54 million631.66 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
23075.35 million69.45 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.92 +0.06 (+0.25%)
As of 02:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$32.46 +0.40 (+1.26%)
As of 02:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

SpringWorks Therapeutics stock logo

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)
As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.